RESEARCH ARTICLE

Inadequate Nutritional Status of Hospitalized Cancer Patients

Ali Alkan¹, Dilha Mizrak², Filiz Cay Shener², Gunogor Utkan¹

ABSTRACT

Objective: In oncology practice, nutrition and also metabolic activity are essential to support the nutritional status and prevent malignant cachexia. It is important to evaluate the patients and plan the maneuvers at the start of the therapy. The primary objective of the study is to define the nutritional status of hospitalized patients and the factors affecting it in order to define the most susceptible patients and maneuvers for better nutritional support.

Methods: Patients hospitalized in oncology clinic for therapy were evaluated for food intake and nutritional status through structured interviews. The clinical properties, medical therapies, elements of nutritional support were noted and predictors of inadequate nutritional status (INS) were analyzed.

Results: Four hundred twenty three patients, between 16-82 years old (median: 52) were evaluated. Nearly half of the patients (185, 43%) reported a better appetite at home than in hospital and declared that hospitalization is an important cause of loss of appetite (140/185, 75.6%). Presence of nausea/vomiting (N/V), depression, age less than 65 and use of non-steroidal anti-inflammatory drugs (NSAIDs) were associated with increased risk of INS in hospitalized cancer patients. On the contrary, steroid medication showed a positive impact on nutritional status of cancer patients.

Conclusion: N/V, younger age, presence of depression and NSAIDs medication were associated with INS in hospitalized cancer patients. Clinicians should pay more attention to this group of patients. In addition, unnecessary hospitalizations and medications that may disturb oral intake must be avoided. Corticosteroids are important tools for managing anorexia and INS.

Key words: Inadequate nutritional status, malnutrition, cancer cachexia.

INTRODUCTION

Palliative care is an important part of oncology practice and good practice can provide better quality of life. The presence of malignancy and associated malnutrition is inevitable. In addition, nutritional support is a crucial part of palliative care and usually difficult to manage. Malnutrition, which has an incidence approaching up to 98% in cancer patients, causes increased infection rates, complications, mortality and prolonged hospitalizations [1-3]. To identify malnourished patients and prevent catastrophic results of malnutrition, cancer patients should be evaluated for nutritional status (NS). Nutritional status is tried to be evaluated with anthropometric, laboratory and subjective measures but the heterogeneity of clinical status, body composition and medications can confound the results of the evaluation [1].

Malnutrition in cancer patients is multifactorial. Tumor related obstructive symptoms, especially in the gastrointestinal and head and neck tumors are the main cause of decreased oral intake [4,5]. Metabolic changes related to the tumor, decreased appetite and performance status, nausea and fatigue can affect the diet [6,7]. Besides tumor related causes, patients are also affected by both the cytotoxic
and other miscellaneous drugs. Oral intake of cancer patients is affected not only by the primary disease and therapy related consequences, but also by the psychosocial environment exposed during therapy. Although cancer related cytokines, cancer related metabolic changes, chemotherapeutic related anorexia are well studied, psychosocial issues are not clearly understood [8,9].

Evaluation and management of malnutrition and cancer cachexia is well analyzed and precious recommendations are present. However, management can be challenging in different populations with different sociocultural background. In the light of the limited data on cancer related malnutrition and management in our population [10-12], we evaluated the nutritional status of patients hospitalized in oncology clinic and tried to explore the factors affecting the nutritional status. The primary objective of the study is to define the nutritional status of hospitalized patients and the factors affecting it in order to define the most susceptible patients and maneuvers for better nutritional support.

**METHODS**

Between January 2013 and September 2014, patients hospitalized in oncology inpatient unit, Ankara University School of Medicine, medical oncology department, were eligible to enter the study. The patients treated in our inpatient clinic were mainly a group of patients hospitalized either for palliative support or medical therapy. Patients with any degree of neurocognitive or neuropsychiatric impairment and comorbidities in whom special diet should be practiced (hypertension, diabetes mellitus, heart failure) were excluded.

Participants were evaluated through structured interviews. The clinicopathological characteristics of patients (sex, age, body mass index (BMI), and primary site of the tumor, stage at the time of analysis, smoking and alcohol history) were noted. World Health Organization cutoff points were used to categorize BMI: obese (≥30), overweight (25–29.99), normal (18.5–24.99) and underweight (<18.5). Since the patients were analyzed at any time during their inpatient episode, spent time in the hospital till the questionnaire was recorded. The clinical properties at the time of interview (presence of nausea/vomiting (N/V), diarrhea or fever), interview history with a diettitian, drugs used (especially for appetite, psychiatric disorder, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids) and the parenteral or enteral nutrition support history were evaluated. The nutritional status of the patients was evaluated both during the interviews and direct observation by the staff charged for the interviews. The amount of food consumed during breakfast, lunch and dinner, snacks and the presence of extra food support in addition to supplied by the clinic were recorded. Quantity of the food consumed was recorded as the thirds of the total amount. The amount less than 2/3 of the meal was accepted as inadequate nutritional status (INS) in that meal. 2/3 and more consumption was recorded as “adequate”. The factors associated with INS were analyzed. In addition, patients were also asked for their appetite in the hospital compared to their home.

Institutional Ethics Committee approved the study protocol, and the study was in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. All persons gave their informed consent prior to their inclusion in the study.

**RESULTS**

Four hundred twenty three patients, between 16-82 years old (median: 52) were evaluated (Table-1). Male predominant group (75.7%) was mostly followed with a diagnosis of lung cancer. Body mass index of the patients ranged from 13.5 to 41.1 (median=24.3) kg/m². One third of the patients were under chemotherapy at the time of evaluation. There were N/V in 65(15.4%), diarrhea in 23 (5.4%) and fever in 42 (9.9%) patients. 77 patients (18.2%) had a diagnosis of depression and were under antidepressant therapy. In addition, 115 (27.2%) and 31 (7.3%) patients were under corticosteroid and anabolizing medication, respectively. While 45 (10.6%) patients were supported with enteral nutrition, 42 (9.9%) patients were under parenteral nutritional support.

Nearly half of the patients (185, 43%) reported a better appetite at home than in hospital and declared that hospitalization is an important cause of loss of appetite (140/185, 75.6%). One third of the patients (134, 31.7%) were eating extra food in addition to the meals provided by the hospital. The poor quality of the food provided by the hospital was the most reported reason for extra food consumption. Most of the patients reported that they ate their meals, 79.9% in breakfast, 72.8% in lunch and 74.2% in dinner. When the amount consumed was analyzed, percentage of patients who ate all the serving was 48.0%, 44.7% and 42.3% for breakfast, lunch and dinner respectively. The most important reason for not eating was loss of appetite (72.4%). The percentage of patients who ate “adequate” was 61.0%, 56.3%, 54.8% for breakfast, lunch and dinner, respectively.

The analysis of factors associated with INS was summarized in Table 2. When nutritional status was evaluated for breakfast;
The multivariate analysis showed that, younger age (<65), N/V, depression, NSAIDs usage were associated with INS (Table 3). The multivariate analysis of factors associated with INS-lunch concluded that N/V, younger age, depression, NSAIDs usage and presence of diarrhea were associated with INS. The multivariate analysis of factors associated with INS-dinner resulted in an increased risk with N/V, younger age, depression and NSAIDs. In all meals, presence of corticosteroid medication was related with decreased risk of INS.

| Characteristics                  | N (%) |
|----------------------------------|-------|
| **Primary Site**                 |       |
| Lung                             | 133 (31.4) |
| Colorectal                       | 68 (16.1) |
| Sarcoma/Bone Tm                  | 68 (16.1) |
| Gastric                          | 41 (9.7)  |
| Other                            | 113 (26.7) |
| Gastrointestinal System          | 109 (25.8) |
| Other                            | 314 (74.2) |
| **BMI (Kg/m²)**                  |       |
| Underweight                      | 66 (15.6) |
| Normal                           | 177 (41.8) |
| Overweight                       | 89 (21.0) |
| Underweight                      | 91 (21.5)  |
| **Duration of Hospitalization (Day)** |       |
| Median (Range)                   | 9 (1-77)  |
| Chemotherapy During Evaluation   | 153 (36.2) |

BMI: Body Mass Index

**DISCUSSION**

In our analysis, presence of nausea/vomiting, depression, age less than 65 and use of NSAIDs were associated with increased risk of INS in hospitalized cancer patients. On the contrary, steroid medication showed a positive impact on nutritional status of cancer patients.

In cancer patients, with the progression of disease, malignant cachexia which is characterized by loss of weight, anorexia, asthma and anemia ensues. Furthermore, with the increasing tumor size and metabolic activity, severe energy depletion becomes a problem. Cachexia is the cause of 22% of deaths in cancer patients. So, in addition to treating the primary pathology, the management of cachexia is an important part of the palliation [13]. Malnutrition is an important challenger of disease process. The prevalence of malnutrition has been estimated to range between 15% and 80% [14]. In addition, it has been associated with reduced quality of life, decreased response to treatment, increased risk of chemotherapy-induced toxicity and a reduction in survival [15]. Besides psychological support; megestrol acetate and dexamethasone as an appetite stimulant, antidepressant medication for depression related anorexia and metoclopramide for dyspepsia may further improve oral intake [16]. Enteral nutritional support and parenteral nutrition in prolonged negative nitrogen balance are further options [17,18].

In our study, hospitalized cancer patients with different properties were analyzed. The past experiences, medication and psychosocial factors are important for oral intake. Especially only by hospitalization, patients’ nutrition progressively deteriorates [19]. This factor may be a result of the low quality of food, relations with other patients and diet recommended by doctors, so unnecessary inpatient follow-ups must be avoided.

The analysis of our cohort also showed a deterioration of NS with prolonged hospitalization. N/V related with primary disease, therapy toxicity or psychological issue is an important and challenging symptom in oncology practice. Our analysis confirmed the importance of N/V control on NS. In addition, site of the primary disease is an important predictor. Gastrointestinal malignancies have been associated with an increased risk of malnutrition [1,20]. In our cohort, even though it's not statistically significant, gastrointestinal malignancies were associated with INS and 72% of enteral-parenteral nutrition was performed in GIS malignancies. In this group, local recurrences and anatomical alterations due to surgeries are important causes of decreased oral intake. Furthermore, clinicians should pay more attention to them.

Depression is a precipitating factor for anorexia and well documented risk factor for malnutrition in chronic diseases. However, association between depression and malnutrition in cancer patients has been less clarified [21-23]. Britton et al. found depression as a risk factor for malnutrition of head and neck cancer patients and proposed a short depression screen to predict malnutrition [24]. The analysis by Daudt et al. showed that depression was the most significant predictor of increased nutritional risk in colorectal cancer patients [25]. Our analysis concluded an important association between depression and INS. This result pointed out the importance of psychological support in hospitalized cancer patients. There is conflicting data about age and malnutrition. A positive correlation has been shown between age and malnutrition risk [1,26]. However, in some of the date in literature, the association couldn't be demonstrated [27]. Similar with the data by Defranchi et al. [19] we documented young age as a risk factor for INS. Effects of drugs used for comorbidities are inevitable. In undernourished cancer patients, anti-inflammatory drugs have been associated with increased survival [28] and indomethacin has been shown to be effective in improvement of body composition during cancer process in rat model [29]. NSAIDs are important components of pain management in oncology practice. Unfortunately, there is no data about NSAID usage and its clinical consequences on NS. Pain is a well-defined risk factor for malnutrition [20,30,31]. In our study, pain was not associated with INS in multivariate
analysis. Irrespective of pain, NSAIDs were related with worse NS. In the cohort, all patients were under proton pump therapy. NSAID related dyspepsia should be further analyzed for the etiology of INS in hospitalized patients and these drugs should be used more cautiously. Corticosteroids are widely used in oncology practice. Short courses of corticosteroids can be used as an appetite stimulant [32,33]. In our analysis, presence of corticosteroid medication either for emesis, edema or malnutrition, was associated with improvement in oral intake in hospitalized cancer patients. Anabolic steroids are widely used as an appetite stimulant [34]. However, their effect couldn’t be demonstrated in our analysis. Instead of anabolic drugs, cautiously used steroids can be a good option for management of INS.

In conclusion, N/V, younger age, presence of depression and NSAID medication were associated with INS in hospitalized cancer patients. Clinicians should pay more attention to this group of patients. In addition, unnecessary hospitalizations and medications that may disturb oral intake must be avoided. Corticosteroids are important tools for managing anorexia and INS.

### Table 2. Predictors of inadequate nutritional status

| Predictors          | Inadequate Breakfast (N, %) | P   | Inadequate Lunch (N, %) | P   | Inadequate Dinner (N, %) | P   |
|---------------------|-----------------------------|-----|-------------------------|-----|--------------------------|-----|
| Sex                 |                             |     |                         |     |                          |     |
| Male                | 120 (37.5)                  | 0.15| 140 (43.8)              | 0.54| 139 (43.4)               | 0.12|
| Female              | 45 (43.7)                   |     | 45 (43.7)               |     | 52 (50.5)                |     |
| Age                 |                             |     |                         |     |                          |     |
| ≥65                 | 16 (20.5)                   | <0.001| 14 (17.9)               | <0.001| 22 (28.2)               | 0.001|
| <65                 | 149 (43.2)                  |     | 171 (49.6)              |     | 169 (49.0)               |     |
| Primary Tm Site     |                             |     |                         |     |                          |     |
| Gastrointestinal    | 44 (40.4)                   | 0.41| 50 (45.9)               | 0.34| 50 (45.9)                | 0.47|
| Other               | 121 (38.5)                  |     | 135 (43.0)              |     | 141 (44.9)               |     |
| Time Spent in Hospital |                         |     |                         |     |                          |     |
| ≥9 Days             | 94 (43.5)                   | 0.03| 99 (45.8)               | 0.21| 102 (47.2)               | 0.21|
| <9 Days             | 71 (34.3)                   |     | 86 (41.5)               |     | 89 (43.0)                |     |
| Nausea/Vomiting     |                             |     |                         |     |                          |     |
| Present             | 44 (67.7)                   | <0.001| 50 (76.9)               | <0.001| 49 (75.4)               | <0.001|
| Absent              | 121 (33.8)                  |     | 135 (37.7)              |     | 142 (39.7)               |     |
| Diarrhea            |                             |     |                         |     |                          |     |
| Present             | 12 (52.2)                   | 0.13| 17 (73.9)               | 0.003| 16 (69.6)                | 0.014|
| Absent              | 153 (38.3)                  |     | 168 (42.0)              |     | 175 (43.8)               |     |
| Fever               |                             |     |                         |     |                          |     |
| Present             | 19 (45.2)                   | 0.23| 21 (50.0)               | 0.24| 24 (57.1)                | 0.06|
| Absent              | 146 (38.3)                  |     | 164 (43.0)              |     | 167 (43.8)               |     |
| Pain                |                             |     |                         |     |                          |     |
| Present             | 116 (47.3)                  | <0.001| 120 (49.0)              | 0.007| 124 (50.6)               | 0.005|
| Absent              | 49 (27.5)                   |     | 65 (36.5)               |     | 67 (37.6)                |     |
| Chemotherapy        |                             |     |                         |     |                          |     |
| Present             | 40 (26.1)                   | <0.001| 53 (34.6)               | 0.003| 57 (37.3)                | 0.009|
| Absent              | 125 (46.3)                  |     | 132 (48.9)              |     | 134 (49.6)               |     |
| Anabolizing Drugs   |                             |     |                         |     |                          |     |
| Present             | 11 (35.5)                   | 0.41| 13 (41.9)               | 0.49| 14 (45.2)                | 0.57|
| Absent              | 154 (39.3)                  |     | 172 (43.9)              |     | 177 (45.2)               |     |
| NSAIDs              |                             |     |                         |     |                          |     |
| Present             | 45 (64.3)                   | <0.001| 43 (61.4)               | 0.001| 45 (64.3)                | <0.001|
| Absent              | 120 (34.0)                  |     | 142 (40.2)              |     | 146 (41.4)               | <0.001|
| Depression/Antidepressant |                         |     |                         |     |                          |     |
| Present             | 45 (58.4)                   | <0.001| 48 (62.3)               | <0.001| 46 (59.7)               | <0.001|
| Absent              | 120 (34.7)                  |     | 137 (39.6)              |     | 145 (41.9)               |     |
| Corticosteroids     |                             |     |                         |     |                          |     |
| Present             | 30 (26.1)                   | 0.001| 31 (27.0)               | <0.001| 33 (28.7)                | 0.001|
| Absent              | 135 (43.8)                  |     | 154 (50.0)              |     | 158 (51.3)               |     |

NSAIDs: Non-steroidal anti-inflammatory drugs
| Predictors                        | Inadequate Breakfast | Inadequate Lunch | Inadequate Dinner |
|----------------------------------|----------------------|------------------|------------------|
|                                  | OR   | CI (95%) | P   | OR   | CI (95%) | P   | OR   | CI (95%) | P   |
| Nausea/ Vomiting                 | 4.8  | 2.5-9.2 | <0.001 | 5.7  | 2.9-11.1 | <0.001 | 4.4  | 2.4-8.7 | <0.001 |
| Age <65                          | 2.1  | 1.1-3.9 | 0.015 | 3.1  | 1.6-5.8 | <0.001 | 1.7  | 0.9-3.0 | 0.04  |
| Depression/Antidepressant        | 2.5  | 1.4-4.5 | 0.002 | 2.8  | 1.4-4.8 | <0.001 | 2.2  | 1.1-3.6 | 0.006 |
| Diarrhea                         | 1.3  | 0.5-3.4 | 0.54  | 3.2  | 1.1-9.1 | 0.033 | 2.0  | 0.8-6.2 | 0.13  |
| Steroid                          | 0.5  | 0.2-0.8 | 0.014 | 0.4  | 0.2-0.7 | 0.001 | 0.4  | 0.2-0.6 | 0.001 |
| NSAIDs                           | 3.3  | 1.8-6.0 | <0.001 | 2.2  | 1.2-4.0 | 0.009 | 2.4  | 1.3-4.4 | 0.003 |
| Pain                             | 1.8  | 0.9-3.5 | 0.09  | 1.3  | 0.6-2.5 | 0.40  | 1.6  | 0.8-3.1 | 0.14  |
| Chemotherapy                     | 0.4  | 0.3-1.3 | 0.27  | 0.7  | 0.3-1.0 | 0.40  | 0.9  | 0.4-1.1 | 0.93  |
| Female Sex                       | 1.4  | 0.8-2.3 | 0.17  | 1.3  | 0.9-2.3 | 0.17  |      |          |       |
| ≥9 Days Hospitalization          | 0.9  | 0.5-1.5 | 0.82  |      |          |       |      |          |       |

NSAIDs: Non-steroidal anti-inflammatory drugs

Declaration of Conflicting Interests: The authors declare that they have no conflict of interest.

Financial Disclosure: No financial support was received.

The report has been written with contributions of all authors and all authors are in agreement with the content of the manuscript.

REFERENCES

1. Zhang L, Lu Y, Fang Y. Nutritional status and related factors of patients with advanced gastrointestinal cancer. Br J Nutr. 2014;111:1239-44.
2. Laky B, Janda M, Kondalsamy-Chennakesavan S, Cleghorn G, Obermair A. Pretreatment malnutrition and quality of life - association with prolonged length of hospital stay among patients with gynecological cancer: A cohort study. BMC Cancer. 2010;10:232.
3. Gupta D, Vashi PG, Lammersfeld CA, Braun DP. Role of nutritional status in predicting the length of stay in cancer: a systematic review of the epidemiological literature. Ann Nutr Metab. 2011;59:96-106.
4. Larsson M, Hedelin B, Johansson I, Athlin E. Eating problems and weight loss for patients with head and neck cancer: a chart review from diagnosis until one year after treatment. Cancer Nurs. 2005;28:425-35.
5. Leistra E, Eerenstein SE, van Aken LH, et al. Effect of early individualized dietary counseling on weight loss, complications and length of hospital stay in patients with head and neck cancer: A comparative study. Nutr Cancer. 2015;1-11.
6. Baracos VE. Cancer-associated cachexia and underlying biological mechanisms. Annu Rev Nutr. 2006;26:435-61.
7. Strasser F. Eating-related disorders in patients with advanced cancer. Support Care Cancer. 2003;11:11-20.
8. Holden CM. Anorexia in the terminally ill cancer patient: the emotional impact on the patient and the family. Hosp J. 1991;7:73-84.
9. Hopkinson JB. Psychosocial impact of cancer cachexia. J Cachexia Sarcopenia Musc. 2014;5:89-94.
10. Topkan E, Yavuz AA, Ozylkan O. Cancer cachexia: pathophysiologic aspects and treatment options. Asian Pac J Cancer Prev. 2007;8:445-51.
11. Akbulut G. New perspective for nutritional support of cancer patients: Enteral/parenteral nutrition. Exp Ther Med. 2011;2:675-84.
12. Kanat O, Cubukcu E, Avci N, et al. Comparison of three different treatment modalities in the management of cancer cachexia. Tumori. 2013;99:229-33.
13. Argiles JM, Busquets S, Lopez-Soriano FJ. The pivotal role of cytokines in muscle wasting during cancer. Int J Biochem Cell Biol. 2005;37(10):2036-46.
14. von Haehling S, Anker SD. Cachexia as major underestimated unmet medical need: facts and numbers. Int J Cardiol. 2012;161:121-3.
15. von Meyenfeldt M. Cancer-associated malnutrition: an introduction. Eur J Oncol Nurs. 2005;9 Suppl 2:S35-8.
16. Cuvelier GD, Baker TJ, Peddie EF, et al. A randomized, double-blind, placebo-controlled clinical trial of megestrol acetate as an appetite stimulant in children with weight loss due to cancer and/or cancer therapy. Pediatr Blood Cancer. 2014;61:672-9.
17. Tsoli M, Robertson G. Cancer cachexia: malignant inflammation, tumourkines and metabolic mayhem. Trends Endocrinol Metab. 2013;24:174-83.
18. von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle. 2010;1(1):1-5.
19. Barritta de Defranchi RL, Bordalejo A, Canueto I, Villar A, Navarro E. Evolution of nutritional status in patients with autologous and allogeneic hematopoietic stem cell transplant. Support Care Cancer. 2015;23:1341-7.
20. Dias do Prado C, Alvares Duarte Bonini Campos J. Nutritional status of patients with gastrointestinal cancer receiving care in a public hospital; 2010-2011. Nutr Hosp. 2013;28:405-11.
21. Duffy SA, Ronis DL, Valenstein M, et al. Depressive symptoms, smoking, drinking, and quality of life among head and neck cancer patients. Psychosomatics. 2007;48(2):142-8.
22. Nho JH, Kim SR, Kwon YS. Depression and appetite: predictors of malnutrition in gynecologic cancer. Support Care Cancer. 2010-2011. Nutr Hosp. 2013;28:405-11.
23. Santarpia L, Contaldo F, Pasanisi F. Nutritional screening and early treatment of malnutrition in cancer patients. J Cachexia Sarcopenia Muscle. 2011;2:27-35.
24. Britton B, Clover K, Bateman L, et al. Baseline depression predicts malnutrition in head and neck cancer patients undergoing radiotherapy. Support Care Cancer. 2012;20:335-42.
25. Daudt HM, Cosby C, Dennis DL, Payeur N, Nurullah R. Nutritional and psychosocial status of colorectal cancer patients referred to an outpatient oncology clinic. Support Care Cancer. 2012;20:1417-23.
26. Gomez Valiente da Silva H, Fonseca de Andrade C, Bello Moreira AS. Dietary intake and nutritional status in cancer patients; comparing adults and older adults. Nutr Hosp. 2014;29:907-12.
27. Fernandez Lopez MT, Saenz Fernandez CA, de Sas Prada MT, et al. [Malnutrition in patients with cancer; four years experience]. Nutr Hosp. 2013;28:372-81.
28. Lundholm K, Gelin J, Hyltander A, et al. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res. 1994;54:5602-6.
29. Gelin J, Andersson C, Lundholm K. Effects of indomethacin, cytokines and cyclosporin A on tumor growth and the subsequent development of cancer cachexia. Cancer Res. 1991;51:880-5.
30. Fazal S, Saif MW. Supportive and palliative care of pancreatic cancer. JOP. 2007;8:240-53.
31. Varadhan KK, Neal KR, Dejong CH, Fearon KC, Ljungqvist O, Lobo DN. The enhanced recovery after surgery (ERAS) pathway for patients undergoing major elective open colorectal surgery: a meta-analysis of randomized controlled trials. Clin Nutr. 2010;29:434-40.
32. Gullett N, Rossi P, Kucuk O, Johnstone PA. Cancer-induced cachexia: a guide for the oncologist. J Soc Integr Oncol. 2009;7:155-69.
33. Paulsen O, Klepstad P, Rosland JH, et al. Efficacy of methylprednisolone on pain, fatigue and appetite loss in patients with advanced cancer using opioids: a randomized, placebo-controlled, double-blind trial. J Clin Oncol. 2014;32:3221-8.
34. Aoyagi T, Terracina KP, Raza A, Matsubara H, Takabe K. Cancer cachexia, mechanism and treatment. World J Gastrointest Oncol. 2015;7:17-29.